Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
The SOXRC regimen significantly improved pCR compared with SOX alone in patients with G/GEJ adenocarcinoma with a tolerable safety profile.
Authors
- Yantao Tian (ORCID: https://orcid.org/0000-0001-6479-7547)
- Wei Wu (ORCID: https://orcid.org/0000-0003-4019-7920)
- Jing Zhuang
- Lin Yang (ORCID: https://orcid.org/0000-0002-7594-3770)
- Jianhong Dong
- Dan Wu (ORCID: https://orcid.org/0000-0002-6661-2961)
- Zhiguo Hou (ORCID: https://orcid.org/0000-0001-8190-4690)
- Yanan Zheng (ORCID: https://orcid.org/0000-0002-9823-0191)
- Kai Yin (ORCID: https://orcid.org/0000-0002-3351-4222)
- Zhenqiang Wang
- Lixin Jiang (ORCID: https://orcid.org/0009-0005-1229-4784)
- Rongrong Zheng (ORCID: https://orcid.org/0009-0001-0052-5128)
- Changhong Lian (ORCID: https://orcid.org/0000-0003-3215-8673)
- Tao Xia (ORCID: https://orcid.org/0000-0003-3014-4825)
- Chengxue Dang
- Xixun Wang
- Zhenggang Zhu (ORCID: https://orcid.org/0000-0003-4769-5463)
- Junsheng Peng (ORCID: https://orcid.org/0000-0002-7975-4176)
- Fei Yuan (ORCID: https://orcid.org/0000-0003-0541-9479)
- Aimin Zhang (ORCID: https://orcid.org/0000-0003-2333-5957)
- Hongzhi Wang (ORCID: https://orcid.org/0000-0003-3834-6050)
- Jian Chen (ORCID: https://orcid.org/0000-0002-2542-9669)
- Hao Chen (ORCID: https://orcid.org/0000-0002-8400-3780)
- Chen Li (ORCID: https://orcid.org/0000-0002-7157-5202)
- Yuting Chen (ORCID: https://orcid.org/0000-0002-0262-9721)
- Yingwei Xue (ORCID: https://orcid.org/0000-0002-8721-6263)
- Xi Zhao (ORCID: https://orcid.org/0000-0002-1513-9852)
- Qian Wang (ORCID: https://orcid.org/0000-0003-1828-434X)
- Dazhi Xu (ORCID: https://orcid.org/0000-0002-9515-3629)
- Sanrong Xu (ORCID: https://orcid.org/0000-0003-4866-7296)
- Heli Liu (ORCID: https://orcid.org/0000-0002-3443-6174)
- Qun Zhao (ORCID: https://orcid.org/0000-0002-5644-3674)
- Zhichao Zheng (ORCID: https://orcid.org/0000-0001-5812-8937)
- Zheng Shi (ORCID: https://orcid.org/0000-0003-4144-6204)
- Luchuan Chen (ORCID: https://orcid.org/0000-0003-3362-447X)
- Benyan Zhang
- Xiangdong Cheng
- Ping Zhao
- Tao Wu
- Kang Wang (ORCID: https://orcid.org/0000-0002-3975-8295)
- Bo Liang (ORCID: https://orcid.org/0000-0003-4732-1488)
Institutions
- Hebei Medical University (CN)
- Jiangsu University (CN)
- Central South University (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Sciences (CN)
- Changzhi Medical College (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Ruijin Hospital (CN)
- Yuhuangding Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Zhejiang Cancer Hospital (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Changhai Hospital (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Lanzhou University Second Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Changchun 208 Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
- Henan Cancer Hospital (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Fujian Provincial Cancer Hospital (CN)
- Tang Du Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Hainan Medical College Hospital (CN)
- Xiangya Hospital Central South University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1200/jco.24.00795
- Citations
- 36
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 15.08
Funders
- Beijing Xisike Clinical Oncology Research Foundation